PXS US FDA Convenes Advisory Committee for Bronchitol |
26/03/19 | | | Share |
|
PXS Becoming a substantial holder |
05/03/19 | | | Share |
|
PXS Ceasing to be a substantial holder |
04/03/19 | | | Share |
|
PXS Boehringer Completes Enrollment of Phase 2A Trial in NASH |
25/02/19 | | | Share |
|
PXS Pharmaxis Commences Phase 1 LOX Clinical Trial |
22/02/19 | PRICE SENSITIVE | | Share |
|
PXS Half Yearly Report and Accounts |
14/02/19 | PRICE SENSITIVE | | Share |
|
PXS Quarterly Shareholder Update - December 2018 |
30/01/19 | PRICE SENSITIVE | | Share |
|
PXS Appendix 4C - quarterly |
30/01/19 | PRICE SENSITIVE | | Share |
|
PXS Pharmaxis Announces LOXL2 Program Phase 2 Ready |
17/01/19 | PRICE SENSITIVE | | Share |
|
PXS PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USA |
20/12/18 | PRICE SENSITIVE | | Share |
|
PXS Pharmaxis Announces First Relaunch Sales of Aridol in USA |
13/12/18 | PRICE SENSITIVE | | Share |
|
PXS Change in substantial holding |
27/11/18 | | | Share |
|
PXS Appendix 3B - exercise of employee options |
26/11/18 | | | Share |
|
PXS Final Director's Interest Notice |
22/11/18 | | | Share |
|
PXS Change of Director's Interest Notice |
22/11/18 | | | Share |
|
PXS Appendix 3B - Grant of options to CEO |
22/11/18 | | | Share |
|
PXS Results of Meeting |
22/11/18 | | | Share |
|
PXS Pharmaxis AGM - CEO Presentation |
22/11/18 | PRICE SENSITIVE | | Share |
|
PXS Chairman's Address to Shareholders |
22/11/18 | PRICE SENSITIVE | | Share |
|
PXS Pharmaxis AGM - Withdrawal of Resolution |
22/11/18 | | | Share |
|
PXS Investor Research Briefing Presentations |
20/11/18 | | | Share |
|
PXS LOX Inhibitor Program for Pancreatic Cancer Phase 1 Ready |
20/11/18 | PRICE SENSITIVE | | Share |
|
PXS Pharmaxis Releases Positive Results of Phase 1 Clinical Tria |
15/11/18 | PRICE SENSITIVE | | Share |
|
PXS Pharmaxis Investor Research Briefing |
15/11/18 | | | Share |
|
PXS Quarterly Shareholder Update - September 2018 |
26/10/18 | | | Share |
|
PXS Appendix 4C - quarterly |
26/10/18 | PRICE SENSITIVE | | Share |
|
PXS Copy of Corporate Governance Statement |
19/10/18 | | | Share |
|
PXS Appendix 4G |
19/10/18 | | | Share |
|
PXS Annual Report to shareholders |
19/10/18 | | | Share |
|
PXS Notice of Annual General Meeting/Proxy Form |
19/10/18 | | | Share |
|
PXS Updated Investor Presentation |
11/10/18 | | | Share |
|
PXS Positive Phase 1 Results of Phase 1 Study - LOXL2 Inhibitor |
11/10/18 | PRICE SENSITIVE | | Share |
|
PXS Director Retirement |
04/10/18 | | | Share |
|
PXS Change in substantial holding |
26/09/18 | | | Share |
|
PXS Appendix 3B - exercise of employee options |
26/09/18 | | | Share |
|
PXS Change in substantial holding |
25/09/18 | | | Share |
|
PXS Change in substantial holding from AEF |
25/09/18 | | | Share |
|
PXS Appendix 3B - exercise of 25,000 employee options |
21/09/18 | | | Share |
|
PXS Change of Director's Interest Notice - Metters |
21/09/18 | | | Share |
|
PXS Change of Director's Interest Notice - W Delaat |
21/09/18 | | | Share |
|
PXS Change of Director's Interest Notice - Phillips |
21/09/18 | | | Share |
|
PXS Change of Director's Interest Notice - McComas |
21/09/18 | | | Share |
|
PXS Change of Director's Interest Notice - S Buckingham |
21/09/18 | | | Share |
|
PXS Section 708A Notice |
21/09/18 | | | Share |
|
PXS Appendix 3B - Placement Tranche 2 |
21/09/18 | | | Share |
|
PXS Initial Director's Interest Notice - E Rayner |
18/09/18 | | | Share |
|
PXS Director Appointment - Edward Rayner |
18/09/18 | | | Share |
|
PXS Results of Meeting |
17/09/18 | | | Share |
|
PXS Chairman's Introductory Comments to Shareholders |
17/09/18 | | | Share |
|
PXS Investor Presentation |
28/08/18 | | | Share |
|
PXS Notice of Extraordinary General Meeting/Proxy Form |
20/08/18 | | | Share |
|
PXS Notice of initial substantial holder |
17/08/18 | | | Share |
|
PXS Preliminary Final Report |
17/08/18 | PRICE SENSITIVE | | Share |
|
PXS Change in substantial holding |
16/08/18 | | | Share |
|
PXS FDA Factory Approval and Relaunch of Aridol in US Market |
15/08/18 | PRICE SENSITIVE | | Share |
|
PXS Section 708A Notice |
14/08/18 | | | Share |
|
PXS Appendix 3B - Placement Tranche 1 |
14/08/18 | | | Share |
|
PXS Capital Raising Presentation |
06/08/18 | PRICE SENSITIVE | | Share |
|
PXS Pharmaxis Announces A$24m Placement |
06/08/18 | PRICE SENSITIVE | | Share |
|
PXS Trading Halt Announcement - System Upgrade |
06/08/18 | PRICE SENSITIVE | | Share |
|
PXS Trading Halt |
03/08/18 | PRICE SENSITIVE | | Share |
|
PXS Quarterly Shareholder Update - June 2018 |
27/07/18 | PRICE SENSITIVE | 441.24KB | Share |
|
PXS Appendix 4C - quarterly |
27/07/18 | PRICE SENSITIVE | 122.6KB | Share |
|
PXS Proposed Issue of Securities to Chief Executive Officer |
25/07/18 | | 111.76KB | Share |
|
PXS Appendix 3B - Grant of Employee Options and Shares |
25/07/18 | | 130.93KB | Share |
|
PXS Appendix 3B - Exercise of Employee Options |
25/07/18 | | 129.31KB | Share |
|
PXS Appendix 3B - Exercise of Employee Options |
17/07/18 | | 129.32KB | Share |
|
PXS Change of Director's Interest Notice - Expiring Options |
02/07/18 | | 71.02KB | Share |
|
PXS LOXL2 Program Attracts Strong Partner Interest at BIO18 |
14/06/18 | PRICE SENSITIVE | 120.63KB | Share |
|
PXS Quarterly Shareholder Update - March 2018 |
30/04/18 | PRICE SENSITIVE | | Share |
|
PXS Appendix 4C - quarterly |
30/04/18 | PRICE SENSITIVE | | Share |
|
PXS Change in substantial holding |
05/04/18 | | | Share |
|
PXS Change in substantial holding from AEF |
04/04/18 | | | Share |
|
PXS Appendix 3B - Exercise of Employee Options |
08/03/18 | | | Share |
|
PXS Half Yearly Report and Accounts |
15/02/18 | PRICE SENSITIVE | | Share |
|
PXS Investor Presentation - 7 February 2018 |
07/02/18 | | | Share |
|
PXS Investor Presentation - 30 January 2018 |
31/01/18 | | | Share |
|
PXS Appendix 4C - quarterly |
29/01/18 | PRICE SENSITIVE | | Share |
|
PXS Quarterly Shareholder Update - December 2017 |
29/01/18 | | | Share |
|
PXS Pharmaxis Earns A$15 Million Milestone Payment |
11/01/18 | PRICE SENSITIVE | | Share |
|
PXS New Australian PBS Listing for Brocnhitol |
02/01/18 | PRICE SENSITIVE | | Share |
|
PXS Pharmaxis Acquires Control, Increases Stake in LOXL2 Program |
14/12/17 | PRICE SENSITIVE | | Share |
|
PXS Appendix 3B - Grant of Employee Peformance Rights |
14/11/17 | | | Share |
|
PXS Change of Director's Interest Notice - G Phillips |
14/11/17 | | | Share |
|
PXS Results of Meeting |
14/11/17 | | | Share |
|
PXS CEO Presentation to 2017 AGM |
13/11/17 | | | Share |
|
PXS Chairman's Address to Shareholders |
13/11/17 | | | Share |
|
PXS Quarterly Shareholder Update - September 2017 |
27/10/17 | | | Share |
|
PXS Appendix 4C - quarterly |
27/10/17 | PRICE SENSITIVE | | Share |
|
PXS Investor Presentation - 23 October 2017 |
23/10/17 | | | Share |
|
PXS Pharmaxis Strengthens Drug Discovery Capability |
19/10/17 | | | Share |
|
PXS Copy of Corporate Governance Statement - 12 October 2017 |
12/10/17 | | | Share |
|
PXS 2017 Appendix 4G - Key to Disclosures |
12/10/17 | | | Share |
|
PXS Notice of 2017 Annual General Meeting/Proxy Form |
12/10/17 | | | Share |
|
PXS 2017 Annual Report to Shareholders |
12/10/17 | | | Share |
|
PXS Appendix 3B - Exercise of employee options |
09/10/17 | | | Share |
|
PXS Investor Presentation |
08/09/17 | | | Share |
|
PXS Interview with CEO - New Phase 2 Study by Boehringer |
08/09/17 | | | Share |
|
PXS Boehringer Initiating Phase 2a Study Diabetic Retinopathy |
08/09/17 | PRICE SENSITIVE | | Share |
|
PXS Antifibrotic LOXL2 Program Clears Preclinical Development |
06/09/17 | PRICE SENSITIVE | | Share |